Phorecast MedLaunch app

Pre-launch · Early access

Medical Device Revenue ForecastingMade SimpleMade FastMade DefensibleMade Investor-ReadyMade Transparent

Phorecast Med helps medical device founders forecast market potential, size TAM, SAM and SOM, and build investor-ready projections from the bottom up. Patient population to procedures to revenue, across global regions, in minutes rather than months.

Launch appSee how it works →

From the team behind PhorecastAI, now built for medical devices.

The problem every device team faces

Traditional device revenue forecasting takes months, costs tens of thousands, and still rests on shaky analogues.

Traditional approach
Phorecast Med
Months of consulting that delay fundraising and BD decisions
Investor-ready forecast in minutes, ready for iteration and pitch use.
Tens of thousands in bespoke consulting fees
Subscription pricing with unlimited iterations as strategy evolves.
Top-down analogues borrowed from unrelated devices
Bottom-up patient-to-procedure funnel built on real epidemiology.
Black-box spreadsheets with undocumented assumptions
Every assumption explicit, sourced, and overridable.
Inputs blended from private benchmarks no one can verify
Curated, referenced benchmarks with confidence flags on the weakest inputs.
US numbers naively scaled to a global figure
Regional procedure-access modeling, because for devices access, not prevalence, sets the real ceiling.

How it works

01

Pick your device and indication

Choose the device category, target condition, and regulatory pathway (510(k), De Novo, or PMA).

02

Model the market

A patient-to-procedure funnel across four global regions, with procedure-access gradients and device-category share.

03

Generate the forecast

A multi-year revenue projection, TAM, SAM and SOM, and a risk-adjusted NPV, with every assumption sourced and editable.

Launch app

See it in action

An illustrative forecast for a transcatheter aortic valve, showing the bottom-up funnel and regional revenue build.

Patient-to-procedure funnel

Bottom-up demand build

Population at risk
12.4M
Diagnosed
8.9M
Treatment-eligible
4.7M
Anatomically suitable
2.2M
Procedures performed
865K
Captured procedures
298K
Net revenue by region · 10-year build

Regional revenue build

Peak 203220262028203020322034
US
Europe
Other developed
Developing

Illustrative figures for demonstration.

Why teams choose Phorecast Med

  • Fast TAM, SAM and SOM for pitch decks and board materials.
  • Sensible default parameters so no forecasting expertise is required.
  • Clean exports that meet institutional standards.

The team

Joaquim Nascimento

Founder and CEO

18+ years in biopharma strategy, market access, and commercial excellence, now applying the same bottom-up forecasting rigor to medical devices.

Marina Lobato

Chief Operating Officer

20+ years in finance and investment management, expert in financial modeling, valuation, and strategic planning.